Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. The company has developed the world's most advanced health check for the health industry, providing risk detection for multiple chronic diseases from a single blood sample. This solution can be scaled to entire populations at a low cost and can replace many current risk assessments. Detecting disease risks on a population level allows for effective targeting and tracking of health interventions and better prevention of chronic diseases. The company operates globally, with its parent company in Finland and subsidiaries in Japan, the United States, Singapore, and the United Kingdom, serving customers in more than 25 countries. Its technology is used in leading health initiatives like the UK Biobank, validated by over 600 peer-reviewed publications.

Key milestones include its Nasdaq Helsinki listing on the Main Market in March 2025, opening laboratories in the UK and the US, launching direct-to-consumer health services, international expansion to countries like Japan and the US, and collaborations with major partners such as Kaiser Foundation and 23andMe. The company has been awarded multiple accolades including Health Innovation of the Year and Finnish Startup of the Year. It combines medical science and extensive data assets to enable preventative healthcare globally.

Headquarters located at Mannerheimintie 164a, 00300 Helsinki, Finland. It has additional offices and laboratories in Estonia, Germany, Japan, Singapore, Sweden, the United Kingdom, and the United States.